ClearPoint Neuro Reports Record 2025 Results, Expands Growth Outlook

The latest announcement is out from ClearPoint Neuro ( (CLPT) ).

ClearPoint Neuro, Inc., based in Solana Beach, Calif., is a global medical device and therapy-enabling company focused on precise navigation for the brain and spine. Its portfolio spans biologics and drug delivery tools, neurosurgery navigation and therapy products, capital equipment and software, and, following its IRRAS Holdings acquisition, neurocritical care solutions, while it targets pre-commercial and future commercial cell and gene therapy delivery with support for more than 60 biopharma partners and over 25 global clinical trials.

ClearPoint Neuro reported record 2025 results on March 17, 2026, with full-year revenue rising 18% to $37.0 million, marking its eleventh straight year of growth, and fourth-quarter revenue up 34% to $10.4 million, while gross margins held at 61–62%. The November 2025 acquisition of IRRAS Holdings expanded the business into neurocritical care, contributed IRRAflow revenue, and was backed by an additional $20 million financing access and a year-end cash balance of $45.9 million, supporting the company’s “Fast. Forward.” growth strategy in a $1 billion market and positioning it for further double-digit expansion and a projected 2026 revenue range of $52–56 million.

The most recent analyst rating on (CLPT) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on ClearPoint Neuro stock, see the CLPT Stock Forecast page.

Spark’s Take on CLPT Stock

According to Spark, TipRanks’ AI Analyst, CLPT is a Neutral.

The score is held back primarily by weak financial performance (large losses, negative ROE, and ongoing cash burn) despite strong top-line growth and solid gross margins. Technical signals are mixed with negative MACD and price below longer-term moving averages, while valuation is difficult to support given negative earnings. The earnings call adds a positive offset due to clearer strategy, improving gross margin, and expected scale benefits from the IRRAS combination.

To see Spark’s full report on CLPT stock, click here.

More about ClearPoint Neuro

ClearPoint Neuro, Inc., based in Solana Beach, Calif., is a global medical device and therapy-enabling company focused on precise navigation for the brain and spine. Its portfolio spans biologics and drug delivery tools, neurosurgery navigation and therapy products, capital equipment and software, and, following its IRRAS Holdings acquisition, neurocritical care solutions. The company targets pre-commercial and future commercial cell and gene therapy delivery, supporting more than 60 biopharma partners and over 25 global clinical trials with its navigation, drug-delivery ecosystem, and clinical specialist network.

ClearPoint Neuro reported record 2025 results on March 17, 2026, with full-year revenue rising 18% to $37.0 million, marking its eleventh straight year of growth, and fourth-quarter revenue up 34% to $10.4 million, while gross margins held at 61–62%. The November 2025 acquisition of IRRAS Holdings expanded the business into neurocritical care, contributed IRRAflow revenue, and was backed by an additional $20 million financing access and a year-end cash balance of $45.9 million, supporting the company’s “Fast. Forward.” growth strategy in a $1 billion market and positioning it for further double-digit expansion and a projected 2026 revenue range of $52–56 million.

Average Trading Volume: 787,712

Technical Sentiment Signal: Sell

Current Market Cap: $328.1M

Learn more about CLPT stock on TipRanks’ Stock Analysis page.